China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical study of its 3D-printed drug product D23, a budesonide ileum-targeted tablet designed to treat IgA nephropathy (IgAN). The study highlights the drug’s precise intestinal targeting and efficacy in addressing the root cause of the disease.
Study Details
D23, a budesonide delayed-release tablet manufactured via Triastek’s proprietary Melt Extrusion Deposition (MED) process, leverages the company’s 3D Microstructure for Intestine Targeting (3DμS®-IT) platform. This technology ensures targeted drug release in the ileum, where IgAN originates, maximizing therapeutic benefits.
The clinical trial evaluated drug transport in the gastrointestinal tract using visual markers and analyzed pharmacokinetic (PK) data. Imaging results confirmed D23’s accurate delivery to the ileum, ensuring budesonide acts on critical immune response areas. The PK profile aligned with imaging data, demonstrating predictable drug behavior in vivo.
Technology Insights
Triastek’s 3DμS®-IT platform enables precise control over drug release, a key advantage in treating IgAN. By focusing on the ileum—the site of disease onset—D23 offers a targeted approach to reducing immune-mediated kidney damage. The successful clinical results position D23 as a potential breakthrough in IgAN therapy, with implications for global patients.-Fineline Info & Tech
Leave a Reply